ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT DATA ON ALX-0761 AT ACR
(Thomson Reuters ONE) -
GHENT, Belgium, 28 October 2013 - Ablynx [Euronext Brussels: ABLX] today
announced that pre-clinical proof-of-concept data from ALX-0761, a Nanobody®
partnered with Merck Serono, will be presented at the Annual Meeting of the
American College of Rheumatology (ACR), 26 to 30 October 2013, San Diego,
California.
The poster presentation will include data from in vivo experiments that assessed
the efficacy of ALX-0761 in a cynomolgus monkey model that mimics human
rheumatoid arthritis. In addition, total target levels of both IL-17A and IL-
17F, pharmacodynamic biomarkers, immunogenicity and drug exposure were analysed.
The proof-of-concept results demonstrated that both IL-17A and IL-17F play a
role in the onset and/or maintenance of rheumatoid arthritis and that ALX-0761
improved the clinical endpoints: X-ray score B (the score for bone erosion or
architectural joint destruction accompanied by bone erosion) and the arthritis
score (the total of the swelling scores of the individual joints). Furthermore,
promising biomarkers were identified to aid further clinical development.
The abstract "Pre-clinical proof-of-concept of ALX-0761, a Nanobody neutralising
both IL-17A and IL-17F in a cynomolgus monkey collagen induced arthritis model"
is available on the ACR website at http://acrannualmeeting.org/. (Presentation
No. 1287; Poster Presentation on 28 October from 8.30 am PDT to 4.00 pm PDT in
the Poster Area).
ALX-0761 is a trivalent Nanobody that neutralises both IL-17A and IL-17F and
that binds to human serum albumin for in vivo half-life extension. It is
currently in development by Ablynx's partner Merck Serono, a division of Merck
KGaA, Darmstadt, Germany.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and six Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx(at)consilium-comms.com
pdf version of the press release:
http://hugin.info/137912/R/1738365/583120.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1738365]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Zecotek's Imaging Technologies Showcased in Partnership with Hamamatsu Photonics at the Nuclear Science Symposium and Medical Imaging Conference in Seoul, KoreaDatum: 28.10.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 309658
Anzahl Zeichen: 4113
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT DATA ON ALX-0761 AT ACR"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
